Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Signal peptide peptidase-like 3 (SPPL3) is a member of the signal peptide peptidase family of intramembrane-cleaving aspartic proteases, related to presenilins[3][4]. SPPL3 is predominantly located in the Golgi apparatus and acts as a sheddase, releasing the active site-containing ectodomains of glycan-modifying glycosidases, thereby regulating glycosylation and protein secretion[6]. Unlike some family members, SPPL3 is not primarily involved in immune surveillance or peptide antigen processing but rather in the modulation of glycosylation patterns, which has implications for cell signaling, tumor biology, and immunomodulation[6][3][4][5]. As of current literature, SPPL3 is not a direct drug target, nor are there established drugs or biomarkers based on its activity, but it is a relevant emerging target for research at the intersection of enzymology, glycomics, and disease biology.
no drugs targeting SPPL3; general mechanism is intramembrane aspartyl protease activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Signal peptide peptidase-like 3 (SPPL3).